Cefuroxime

A second-generation cephalosporin antibiotic, FDA-approved for throat, ear, sinus, bronchitis, skin and urinary infections, gonorrhea and early Lyme disease.

psilodex.org/m/cefuroxime · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~1.2–1.3 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Cefuroxime”, v2026.10.05. psilodex.org/m/cefuroxime

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Generic only in US

FDA-approved for

Pharyngitis/tonsillitis
Acute bacterial otitis media
Acute bacterial maxillary sinusitis
Acute bacterial exacerbations of chronic bronchitis
Uncomplicated skin infections
Uncomplicated urinary tract infections
Uncomplicated gonorrhea
Early Lyme disease (erythema migrans)

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin, and no mechanism linking them has been described.

Human data with psilocybin: No psilocybin data; based on its label
Half-life: ~1.2–1.3 h (FDA label, checked 2026-10-04) Mean elimination half-life after 125–1,000 mg oral tablets.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Cefuroxime axetil tablets (Aurobindo) · FDA label (DailyMed) — revised 2024-05 | 12.3 Table "Mean Elimination Half-life (h) AUC (mcg·h/mL) 125 mg 2.1 2.2 1.2 6.7 250 mg 4.1 2.5 1.2 12.9"
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →